2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 723

Renal Dysfunction and Disease Severity in Scleroderma-Associated Pulmonary Arterial Hypertension
Abstract Number: 318

Replication Analysis of Non-HLA Gene Variants with Prior Evidence of Association with Juvenile Idiopathic Arthritis
Abstract Number: 1863

Resetting the Naming Speed Clock with Methylphenidate (Ritalin)
Abstract Number: 785

Resident Lung Fibroblast Gene Expression Signatures Predict Susceptibility or Resistance to Experimental Lung Fibrosis
Abstract Number: 2639

Residual Disease Activity in Patients with Early Rheumatoid Arthritis Who Were Classified As Being in Remission According to 8 Different Descriptions: Post Hoc Analysis of the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort
Abstract Number: 1586

Resistance Exercise Training for Fibromyalgia: A Systematic Review
Abstract Number: 1971

Resolution of Effects On Bone Turnover Markers and Bone Mineral Density After Discontinuation of Long-Term Bisphosphonate Use
Abstract Number: 2560

Response and Drug Survival of 1^st TNF-Inhibitor in 440 Patients with Psoriatic Arthritis – What Is the Role of Co-Medication with Methotrexate?
Abstract Number: 1140

Response to Adalimumab in 40 Patients with refractory juvenile Idiopathic Arthritis-Associated Uveitis. A Multicenter Study
Abstract Number: 362

Response to Etanercept, but Not Infliximab or Adalimumab, Is Inversely Associated with Body Mass Index
Abstract Number: 2125

Response to Methotrexate Plus Prednisone in Camera II Using a Multi-Biomarker Disease Activity (Vectra^TMDA) Test and DAS28-ESR
Abstract Number: 837

Response to MMF Therapy for Lupus Nephritis Is Independent of Genetic Variation of Inosine Monophosphate Dehydrogenase
Abstract Number: 2444

Restricting Back Pain Is Associated with Disability in Community-Living Older Persons
Abstract Number: 717

Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative
Abstract Number: 2032

Results From a Multicentre International Registry of Familial Mediterranean Fever: Impact of Genetic and Environment Factors On the Expression of a Monogenic Disease in Children

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].